A study was carried out on 135 patients with chronic idiopathic neuropathy (63), neuropathy associated with monoclonal gammopathy (51, including eight with anti-MAG antibody activity) and the Guillain-Barre syndrome (GBS) (21). Serum IgM, IgG and IgA anti-sulphatide antibody titres were compared with titres in 304 patients with other neurological or immunological diseases and in 50 normal subjects. Titres were presented a) as the highest serum dilution at which reactivity could be detected, and b) in the linear region of the optical density curve. A substantial number of patients with neurological or immunological diseases had higher titres than normal subjects.
Abstract
A study was carried out on 135 patients with chronic idiopathic neuropathy (63), neuropathy associated with monoclonal gammopathy (51, including eight with anti-MAG antibody activity) and the Guillain-Barre syndrome (GBS) (21). Serum IgM, IgG and IgA anti-sulphatide antibody titres were compared with titres in 304 patients with other neurological or immunological diseases and in 50 normal subjects. Titres were presented a) as the highest serum dilution at which reactivity could be detected, and b) in the linear region of the optical density curve. A substantial number of patients with neurological or immunological diseases had higher titres than normal subjects. Compared with normal and disease controls, five patients with neuropathy associated with IgMk monoclonal gammopathy had raised titres of IgM antisulphatide antibodies and one patient with GBS had raised IgM, IgG and IgA anti-sulphatide antibodies in the acute phase of the disease. Two patients had a predominantly axonal sensory neuropathy with presenting symptoms of painful paresthesiae and minimal neurological deficit. Three patients had a predominantly demyelinating sensorimotor neuropathy associated with anti-MAG antibody activity. The patient with GBS had extensive sensory loss and antibody titres returned to normal within three weeks. Raised titres of anti-sulphatide antibodies occurred in several types of neuropathy, but all had some degree of sensory impairment and associated immunological abnormality. Raised titres of serum anti-sulphatide antibodies were initially reported in patients with multiple sclerosis, idiopathic thrombocytopaenic purpura and chronic active hepatitis. [1] [2] [3] Recently, these antibodies have been found in predominantly sensory axonal neuropathy, demyelinating neuropathy associated with anti-MAG antibodies and also in the Guillain-Barre syndrome (GBS).s7
To define which subtypes of peripheral neuropathy are associated with raised antisulphatide antibodies, we studied patients with neuropathy and other neurological and immunological diseases, and normal subjects. To compare the results to previously published work4 we determined the mean value plus 3 SD for normal controls by method B, which was 493 AU/l for IgM anti-sulphatide antibodies. When this value was taken as the upper limit of normal, 11 patients with values between 493 and 1950 AU/l had raised antibody activity, of which eight were disease controls. The GBS patient had higher antibody activity for both IgG and IgA, but also seven disease controls for IgG and 24 disease controls for IgA.
We also determined the mean value plus 3 SD of normal and disease controls, which was 952 AU/I for IgM antibodies. One patient with neuropathy associated with monoclonal gammopathy (also positive by method A) and two disease controls had antibody activity between 953 and 1950 AU/i. The 
PATIENTS WITH RAISED ANTI-SULPHATIDE ANTIBODIES
A summary of the clinical and laboratory data of patients with raised anti-sulphatide antibodies is presented in the table. Six patients had raised anti-sulphatide antibodies compared with normal and disease controls by method A. Five of them also had raised antisulphatide antibodies compared with disease controls by method B, and one of them (patient B 1, table) had raised antibodies compared with the mean value plus 3 SD of normal and disease controls. Three clinical presentations were associated with raised anti-sulphatide antibodies:
A) Painful sensory neuropathy Patients Al and A2 had identical presenting complaints of painful nocturnal paresthesiae. Otherwise neurological deficit was minimal and the clinical course was very slowly progressive.
B) Sensorimotor neuropathy associated with anti-MAG antibody activity Three out of eight patients with neuropathy associated with anti-MAG antibody activity also had raised titres of anti-sulphatide antibodies. The anti-MAG and anti-sulphatide antibodies were of the IgMk isotype and absorption of patient serum with sulphatide bound to Octyl-Sepharose resulted in approximately 80% reduction of antibody binding to sulphatide as well as to MAG, suggesting that the IgMk monoclonal antibody reacted with both antigens. As control, absorption of sera with anti-MAG antibodies without anti-sulphatide antibodies did not reduce antibody binding to MAG.
C) GBS
One of 21 patients with GBS had raised antisulphatide antibody titres. This patient had raised IgM, IgG and IgA anti-sulphatide antibodies and had the most profound sensory loss among the 21 patients. Detailed clinical data of the 21 GBS patients were previously published.10 Titres were highest in the acute phase of the disease and returned to the normal range within three weeks. Discussion A substantial number of patients with neurological or immunological diseases had higher anti-sulphatide antibody titres compared with normal subjects. Six patients with peripheral neuropathy had raised anti-sulphatide antibodies compared with normal and disease controls. However, neuropathy associated with raised anti-sulphatide antibodies does not appear to constitute one clinical syndrome. Two patients had a predominantly axonal sensory neuropathy with presenting symptoms of painful paresthesiae and minimal neurological deficit. Three patients had a severe sensorimotor neuropathy with demyelination and raised anti-MAG antibodies and one patient had acute GBS with extensive sensory loss. The chronic neuropathies were all associated with IgM monoclonal gammopathy.
Absorbtion studies in the three patients with raised titres of anti-MAG and anti-sulphatide antibodies suggest that the IgMk monoclonal gammopathy has antibody activity to both antigens. Ilyas et al reported similar results in two of ten patients with anti-MAG antibodies. 5 By using thin-layer chromotography (TLC) anti-sulphatide antibodies were previously found in 65% of patients with GBS, however, disease controls were not studied and 15% of healthy controls also had antisulphatide antibodies.6 In contrast, Ilyas et al did not find raised anti-sulphatide antibodies in GBS by TLC and ELISA, when titres were compared with normal and disease controls.7 In our study only one of 21 GBS patients had raised anti-sulphatide antibody titres. Titres were highest in the acute phase of the disease and returned to the normal range within three weeks suggesting that the antibodies were related to the disease. Raised titres of IgM, IgG or IgA anti-sulphatide antibodies may be an infrequent finding in GBS patients and may be peculiar to patients with extensive sensory loss. However, a larger number of GBS patients will have to be tested to confirm these observations.
From the present study it may be concluded that raised anti-sulphatide antibody titres are not as common as previously suggested by Pestronk et al, who found raised titres in 18 of 64 (28%) patients with sensory ± motor neuropathy.4 The discrepancy may result from the following differences in our assay procedures: a) Pestronk et al defined high titres as those more than 3 SD above the mean value of normal controls. We found that using this method a substantial number of patients with other diseases would have raised titres. We considered antibody titres to be raised when compared with normal and disease controls. b) A significant number of patient sera have relatively high binding to uncoated control wells. In our study values in uncoated control wells were subtracted from values in sulphatide-coated wells for each patient. Using this method only antibody binding to sulphatide was measured. In our study two methods of calculating antibody titres were compared. In method A readings were taken from the last part and in method B from the linear part of the OD curve. The OD curve of each patient has a different shape, which explains intra-individual variations of results from method A or B. Although both methods detect highly elevated antibody titres, we prefer method A for routine use, as values at higher serum dilutions suggest higher affinity antibody binding and may be more accurate. In addition values from method B are more difficult to compare with other laboratories, as not every laboratory may use the same positive control.
The role of anti-sulphatide antibodies in
